# **Tumor Immune Escape: Clinical Observations**

Pedro J. Romero, MD Ludwig Jnstitute of Cancer Research Lausanne, Switzerland pedro.Romero@isrec.unil.ch Cassian Yee, MD Fred Hutchinson Cancer Research Center Seattle, WA cyee@fhcrc.org

# **Tumor Immunotherapy:** Immune Escape

#### 'Manipulated' vs 'Endogenous'



# Tumor Immune Surveillance Innate Immunity

Normal

Tumor





### **Immunoediting and Immunoselection**



Genetic instability, Selection & Expansion

#### TUMOR CELL - ASSOCIATED



#### ACCESSORY CELL - ASSOCIATED



#### Mechanistic Considerations of Tumor Immune Escape

- What makes a tumor site uniquely immunosuppressive?
- Interplay among different regulatory mechanisms and immune cells



#### Mechanistic Considerations of Tumor Immune Escape

- What makes a tumor site uniquely immunosuppressive?
- Interplay among different regulatory mechanisms and immune cells
- Models to identify novel mechanisms of immune escape and evaluate potential solutions?

## <u>Translational Considerations for Evaluating and Overcoming</u> <u>Tumor Immune Escape</u>

- Do these mechanisms exist in vivo?
- Relevance in subverting a clinical response?
- Availability of tools to monitor immune escape ?
- Design of clinical trials to monitor and evaluate these factors?
- Interventions reagents or strategies ?

### <u>Tumor Immune Escape</u> <u>Workshop Participants</u>

Lieping Chen Tyler Curiel Soldano Ferrone Thomas Gajewski Hung Khong Franco Marincola Begonya Comin-Anduix Kim Margolin Steven O'Day Hiroyuki Sakashita Terry Shibuya Jon Wigginton

Mayo Clinic **Tulane University** Roswell Park Univ of Chicago Univ South Alabama NIH Univ of California Los Angeles City of Hope John Wayne Cancer Institute Thomas Jefferson University Univ of California at Irvine NIH